Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Two separate Israeli espionage cases uncover Iran-linked activities in Jerusalem, Ashkelon - 2Bruno Mars tour 2026: How to get tickets for 'The Romantic Tour,' presale times, prices and more
- 3Ober Gabelhorn glacier reveals remains of man missing for over three decades
- 4Nigeria warns its citizens in South Africa to be cautious after march turns violent
- 5The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Surf Spot Mechanics: Bells Beach
- Remarkable Spots for Hot Air Swelling All over The Planet
- Vote in favor of Your #1 sort of pie
- Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- 3D Printers for Specialists
- Vote In favor of Your Favored Kind Of Attire
- Misremembering might actually be a sign your memory is working optimally
